Lucira Health (NASDAQ:LHDXQ) and MyMD Pharmaceuticals (NASDAQ:MYMD) Head to Head Review

Lucira Health (NASDAQ:LHDXQ – Get Rating) and MyMD Pharmaceuticals (NASDAQ:MYMD – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Analyst Ratings

This is a summary of recent ratings for Lucira Health and MyMD Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucira Health	0	0	0	0	N/A
MyMD Pharmaceuticals	0	0	0	0	N/A

Profitability

This table compares Lucira Health and MyMD Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucira Health	-67.54%	-13.55%	-8.47%
MyMD Pharmaceuticals	N/A	-81.66%	-59.00%

Institutional & Insider Ownership

57.0% of Lucira Health shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Comparatively, 3.6% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Lucira Health has a beta of 3.24, meaning that its share price is 224% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.

Earnings and Valuation

This table compares Lucira Health and MyMD Pharmaceuticals’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucira Health	$93.06 million	0.05	-$64.83 million	($3.58)	-0.03
MyMD Pharmaceuticals	N/A	N/A	-$15.20 million	($0.36)	-6.28

MyMD Pharmaceuticals has lower revenue, but higher earnings than Lucira Health. MyMD Pharmaceuticals is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.

Summary

Lucira Health beats MyMD Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

About MyMD Pharmaceuticals

(Get Rating)

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.